Literature DB >> 21956922

Molecular alterations during progression of prostate cancer to androgen independence.

Punit Saraon1, Keith Jarvi, Eleftherios P Diamandis.   

Abstract

BACKGROUND: Prostate cancer is the most commonly diagnosed cancer among men in North America and is a leading cause of death. Standard treatments include androgen deprivation therapy, which leads to improved clinical outcomes. However, over time, most tumors become androgen independent and no longer respond to hormonal therapies. Several mechanisms have been implicated in the progression of prostate cancer to androgen independence. CONTENT: Most tumors that have become androgen independent still rely on androgen receptor (AR) signaling. Mechanisms that enhance AR signaling in androgen-depleted conditions include: AR gene amplification, AR mutations, changes in the balance of AR cofactors, increases in steroidogenic precursors, and activation via "outlaw" pathways. Along with AR signaling, various other AR-independent "bypass" pathways have been shown to operate aberrantly during androgen independence. Changes in the epigenetic signatures and microRNA concentrations have also been implicated in the development of androgen-independent prostate cancer.
SUMMARY: Understanding of the molecular mechanisms that lead to the development of androgen-independent prostate cancer will allow for improved therapeutic strategies that target key pathways and molecules that are essential for these cells to survive.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21956922     DOI: 10.1373/clinchem.2011.165977

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  53 in total

Review 1.  Restoring TGFβ1 pathway-related microRNAs: possible impact in metastatic prostate cancer development.

Authors:  Juliana Inês Santos; Ana Luísa Teixeira; Francisca Dias; Mónica Gomes; Augusto Nogueira; Joana Assis; Rui Medeiros
Journal:  Tumour Biol       Date:  2014-04-25

Review 2.  Ca2+ as a therapeutic target in cancer.

Authors:  Scott Gross; Pranava Mallu; Hinal Joshi; Bryant Schultz; Christina Go; Jonathan Soboloff
Journal:  Adv Cancer Res       Date:  2020-07-09       Impact factor: 6.242

3.  Genetic variants in AR and SHBG and resistance to hormonal castration in prostate cancer.

Authors:  Cátia Monteiro; Marta Velho Sousa; Ricardo Ribeiro; Joaquina Maurício; Avelino Fraga; Rui Medeiros
Journal:  Med Oncol       Date:  2013-02-10       Impact factor: 3.064

Review 4.  Proteomic studies of urinary biomarkers for prostate, bladder and kidney cancers.

Authors:  Steven L Wood; Margaret A Knowles; Douglas Thompson; Peter J Selby; Rosamonde E Banks
Journal:  Nat Rev Urol       Date:  2013-02-26       Impact factor: 14.432

5.  Long non-coding RNA LOC283070 mediates the transition of LNCaP cells into androgen-independent cells possibly via CAMK1D.

Authors:  Lina Wang; Yani Lin; Hui Meng; Chunyan Liu; Jing Xue; Qi Zhang; Chaoyang Li; Pengju Zhang; Fuai Cui; Weiwen Chen; Anli Jiang
Journal:  Am J Transl Res       Date:  2016-12-15       Impact factor: 4.060

6.  Could the kinetin riboside be used to inhibit human prostate cell epithelial-mesenchymal transition?

Authors:  Joanna Dulińska-Litewka; Bartosz Gąsiorkiewicz; Aleksandra Litewka; Dorota Gil; Tomasz Gołąbek; Krzysztof Okoń
Journal:  Med Oncol       Date:  2020-02-06       Impact factor: 3.064

7.  Proteomic profiling of androgen-independent prostate cancer cell lines reveals a role for protein S during the development of high grade and castration-resistant prostate cancer.

Authors:  Punit Saraon; Natasha Musrap; Daniela Cretu; George S Karagiannis; Ihor Batruch; Chris Smith; Andrei P Drabovich; Dominique Trudel; Theodorus van der Kwast; Colm Morrissey; Keith A Jarvi; Eleftherios P Diamandis
Journal:  J Biol Chem       Date:  2012-08-20       Impact factor: 5.157

8.  Quantitative proteomics reveals that enzymes of the ketogenic pathway are associated with prostate cancer progression.

Authors:  Punit Saraon; Daniela Cretu; Natasha Musrap; George S Karagiannis; Ihor Batruch; Andrei P Drabovich; Theodorus van der Kwast; Atsushi Mizokami; Colm Morrissey; Keith Jarvi; Eleftherios P Diamandis
Journal:  Mol Cell Proteomics       Date:  2013-02-26       Impact factor: 5.911

Review 9.  MicroRNAs and drug resistance in prostate cancers.

Authors:  Feng Li; Ram I Mahato
Journal:  Mol Pharm       Date:  2014-04-29       Impact factor: 4.939

10.  Arrestin2 modulates androgen receptor activation.

Authors:  H T Purayil; Y Zhang; A Dey; Z Gersey; L Espana-Serrano; Y Daaka
Journal:  Oncogene       Date:  2014-08-11       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.